1. Home
  2. PHVS vs EZPW Comparison

PHVS vs EZPW Comparison

Compare PHVS & EZPW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PHVS
  • EZPW
  • Stock Information
  • Founded
  • PHVS 2015
  • EZPW 1989
  • Country
  • PHVS Switzerland
  • EZPW United States
  • Employees
  • PHVS N/A
  • EZPW N/A
  • Industry
  • PHVS Biotechnology: Pharmaceutical Preparations
  • EZPW Other Specialty Stores
  • Sector
  • PHVS Health Care
  • EZPW Consumer Discretionary
  • Exchange
  • PHVS Nasdaq
  • EZPW Nasdaq
  • Market Cap
  • PHVS 980.9M
  • EZPW 814.0M
  • IPO Year
  • PHVS 2021
  • EZPW 1991
  • Fundamental
  • Price
  • PHVS $20.06
  • EZPW $15.49
  • Analyst Decision
  • PHVS Buy
  • EZPW Strong Buy
  • Analyst Count
  • PHVS 6
  • EZPW 3
  • Target Price
  • PHVS $37.17
  • EZPW $19.33
  • AVG Volume (30 Days)
  • PHVS 216.0K
  • EZPW 741.9K
  • Earning Date
  • PHVS 08-13-2025
  • EZPW 07-30-2025
  • Dividend Yield
  • PHVS N/A
  • EZPW N/A
  • EPS Growth
  • PHVS N/A
  • EZPW 23.23
  • EPS
  • PHVS N/A
  • EZPW 1.29
  • Revenue
  • PHVS N/A
  • EZPW $1,232,018,000.00
  • Revenue This Year
  • PHVS N/A
  • EZPW $9.33
  • Revenue Next Year
  • PHVS N/A
  • EZPW $6.46
  • P/E Ratio
  • PHVS N/A
  • EZPW $11.88
  • Revenue Growth
  • PHVS N/A
  • EZPW 8.31
  • 52 Week Low
  • PHVS $11.51
  • EZPW $10.56
  • 52 Week High
  • PHVS $26.33
  • EZPW $16.60
  • Technical
  • Relative Strength Index (RSI)
  • PHVS 48.84
  • EZPW 66.39
  • Support Level
  • PHVS $20.06
  • EZPW $13.74
  • Resistance Level
  • PHVS $22.30
  • EZPW $15.49
  • Average True Range (ATR)
  • PHVS 1.13
  • EZPW 0.47
  • MACD
  • PHVS -0.23
  • EZPW 0.19
  • Stochastic Oscillator
  • PHVS 22.84
  • EZPW 95.33

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.

About EZPW EZCORP Inc. Non Voting

EZCORP Inc is a United States-based company engaged in offering pawn loans in the United States and Mexico. It also offers short-term unsecured loans and other consumer financial products, and buy and sell second-hand goods. The operating segments of the company are us Pawn, Latin America Pawn, and other international. us Pawn segment includes all pawn activities in the United States. Latin America Pawn segment includes all pawn activities in Mexico and other parts of Latin America. The company generates revenue from merchandise sales, jewelry scrapping sales, and pawn service charges, of which key revenue is derived from the merchandise sales which are primarily collateral forfeited from pawn lending operations and used merchandise purchased from the customers.

Share on Social Networks: